|
| Wenxin granule and metoprolo for superventricular premature beat: a cost-effectiveness analysis |
| Hits 1654 Download times 1337 Received:April 28, 2016 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2016.09.04 |
| Key Words
Wenxin granule;metoprolo;superventricular premature beat;cost-effectiveness analysis |
| Author Name | Affiliation | E-mail | | HUANG Yue | Tianjin Beichen Chinese Medicine Hospital, Tianjin 300400, China | | | YANG Tao | Tianjin Beichen Chinese Medicine Hospital, Tianjin 300400, China | 512721603@qq.com |
|
| Abstract
|
| [Objective] To compare the combination of Wenxin granule and metoprolo and single metoprolo for superventricular premature beat with cost-effectiveness analysis from health economic evaluation perspective. [Methods] The 136 patients with superventricular premature beat were admitted into our study from October 2014 to October 2015 and divided into 2 groups including combination group and metoprolo group according to treatment plan. After 4 weeks treatment we evaluated the clinical effects and quality of life for the patients in the 2 groups. EQ-5D scale was applied for quality of life evaluation. Eventually these data were used for cost effectiveness analysis. [Results] The cilinical outcome of combination group was better than that in single metoprolo group (P<0.05). The total cost of combination group and single metoprolo group was 326.2 yuan and 22.3 yuan respectively. Therefore the cost effectiveness ratio (CER) was 388.3 and 30.1, and the ICER was 3 039 which means the patients in combination group spend more money but also receive better results. [Conclusion] Combination treatment plan can provide better clinical outcome, however the total cost is also higher than single metoprolo treatment. Therefore the combination treatment maybe not the best choice for all the patients, doctors should choose the right plan according to the patients' actual situation. |
|
